However, combined with standard IC, midostaurin improved overall survival of ND patients with FLT3 mutated AML, as shown in the RATIFY trial where a 7% higher probability of survival after 48 months was seen than in patients treated with IC only [52]. This evidence concerns the gene FLT3 and acute myeloid leukemia.